LSIPR 50 2016: Jean George and Carl Gordon
Name: Jean George
Organisation: Advanced Technology Ventures
Position: General partner
Jean George is a general partner at Advanced Technology Ventures (ATV) and focuses on investments in the biopharmaceutical and medical device sectors. Based in Boston, she also works as a general partner for Lightstone Ventures.
Like many of our Top 50 in the investment field, George been featured on the Forbes Midas List for her various involvements in biopharma companies.
As well as her work with ATV and Lightstone, she was a former member of the scientific advisory board for the Massachusetts Life Sciences Center.
She has more than 20 years’ experience in the biopharmaceutical industry, including ten years at Genzyme where she held a variety of roles in marketing, product and business development. The company became a subsidiary of Sanofi in 2011 following a $20.01 billion buyout deal.
"Like many of our Top 50 in the investment field, George been featured on the Forbes Midas List for her various involvements in biopharma companies."
George is on the board of directors at Acceleron Pharma, based in Cambridge, and was a former board member at Hypnion, which was bought by Eli Lilly in 2007.
Acceleron focuses on ailments including blood cancers and chronic kidney disease, while Hypnion is a neuroscience drug discovery company focused on sleep disorders.
(Image: dennizn / Shutterstock.com)
Name: Carl Gordon
Organisation: OrbiMed
Position: Partner
Carl Gordon is a founding partner and co-head of global private equity at OrbiMed, a New York-based venture capital fund.
From biopharmaceuticals to medical devices, diagnostics and healthcare services, OrbiMed looks for innovations that will help improve healthcare. It has been investing globally for more than 20 years across the healthcare industry, from early-stage private companies to large multinational corporations.
Gordon is one of six partners at the 80-strong firm, which comprises distinguished scientific, medical, investment and other professionals. Together, they manage around $15 billion worth of public and private company investments.
Gordon’s achievements include presiding over the sale of cancer drug maker Aragon Pharmaceuticals to Johnson & Johnson in a 2013 deal that was valued at up to $1 billion.
"they manage around $15 billion worth of public and private company investments."
Before joining OrbiMed, he was a senior biotechnology analyst at biopharmaceutical investment advisory group Mehta and Isaly from 1995 to 1997.
He was a fellow at The Rockefeller University from 1993 to 1995 and was included on the Forbes Midas List of top venture capital investors in 2014.
